1 completed, 1 not yet recruiting, 1 withdrawn. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
Follow Fibronostics USA, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population. Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | Not yet recruiting | Fibronostics USA, Inc | 100 | 2025-05-01 | 2025-03-13 | |
| Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD. LIVERFASt - Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis | Not applicable | Completed | Fibronostics USA, Inc | 241 | 2021-01-07 | 2022-08-02 |
| Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy LiverFASt - NAFLD, NASH | Withdrawn | Fibronostics USA, Inc | 2019-09-01 | 2021-02-03 |
Fatty Liver (2) · Non-alcoholic Fatty Liver Disease (2) · Fibrosis (1) · Hepatitis (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Motor Activity (1)
United States (3)
Imtiaz Alam, MD (1) · Parth Shah, MD (1) · Ronald Quiambao, MD (1) · Sven Henrichwark (1)